Press release
Primary Hepatocytes Market Size Worth US$ 486 Million with 6.6% CAGR by 2034: Fact.MR Report
Primary Hepatocytes Market
With liver toxicity studies exploring new applications and therapeutic approaches, the demand for reliable sources of fresh hepatocytes to support in vitro liver models is expected to grow significantly in the near future.
For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9643
What Emerging Trends Are Driving Growth in the Primary Hepatocytes Market?
"Surge in In Vitro Liver Toxicology Testing and Growing Regulatory Focus on Drug Safety"
As the healthcare landscape increasingly shifts toward personalized medicine, there is a growing demand for hepatocytes that accurately reflect individual genetic variations. In response, key industry players are expanding their offerings of primary hepatocytes sourced from diverse genetic backgrounds to support customized drug response analysis and liver toxicity research.
Advancements in hepatocyte preservation techniques have also significantly improved the viability and functionality of cryopreserved cells. As a result, suppliers are intensifying their efforts to refine cryopreservation technologies, aiming to deliver high-quality, ready-to-use hepatocytes that meet evolving research and clinical requirements.
Country-wise Insights
In East Asia, industry participants are catering to the region's robust pharmaceutical sector by supplying hepatic cells essential for understanding liver disease progression and formulating effective treatments. The region's dynamic healthcare infrastructure and research investments are further fueling demand for primary hepatocytes.
In North America, the primary hepatocytes market is projected to reach a valuation of approximately US$ 88 million by 2024. A key growth driver in this region is the expanding network of biobanking programs, which ensures a steady supply of diverse hepatocyte samples for a wide range of research and drug development applications.
According to Fact.MR, the market for primary hepatocytes is expected to grow at a CAGR of 5.4%, reaching a total value of about US$ 150 million by the end of 2034.
Category-wise Insights
Biopharmaceutical companies account for over half of the total demand for primary hepatocytes. These cells are critical for early-stage drug testing, making them indispensable in drug discovery pipelines. The segment is forecast to grow at a CAGR of 6.1%, with projected revenues reaching US$ 235.8 million by 2034.
Academic and research institutions are also showing increased interest in primary hepatocytes, driven by their applications in collaborative research efforts. Partnerships between hepatocyte suppliers and academic organizations are expanding the scope of innovation in liver cell research.
Competitive Landscape
Leading players in the global primary hepatocytes market include Thermo Fisher Scientific, Corning Inc., Lonza, Axol Bioscience Ltd., LifeNet Health, SEKISUI XenoTech, LLC, Cytes Biotechnologies, Cell Biologics, Inc., ZenBio, Inc., BioIVT, ScienCell Research Laboratories, Inc., Kerafast, Takara Bio Inc., and Kosheeka.
Established vendors have cultivated long-term collaborations with researchers focused on bioengineered liver regeneration and therapeutic innovations. Meanwhile, new entrants are gaining traction by exploring novel bioengineering applications for liver cell assays.
Recent Developments
In May 2022, BioIVT, a U.S.-based company, introduced a new line of human primary hepatic cells, including high-purity Kupffer cells. These additions aim to support the development of therapies for various liver diseases.
In January 2022, Charles River Laboratories acquired HemaCare Corp., a major supplier of primary hepatocytes for both research and clinical use. This acquisition is part of Charles River's strategy to expand its capabilities in the fast-growing cell therapy market.
Browse Full Report: https://www.factmr.com/report/primary-hepatocytes-market
Key Segments Covered by Primary Hepatocytes Industry Survey Report
By Product Type:
Cryopreserved Suspension Hepatocytes
Fresh Suspension Hepatocytes
3D (Spheroid) Hepatocytes
Expanded Hepatocytes (Plateable)
Non-characterized Hepatocytes
By Species Type:
Humans
Rats
Mice
Dogs
Monkeys
Horses
Other Species
By Application or Assay:
Cell Viability Assays
Cytochrome Enzyme Activity
High Content Cytotoxicity
Transporter Inhibition Assays
In Vitro Intrinsic Clearance
Phospholipoid Assays
Other Applications or Assays
By End User Verticals:
Biopharmaceutical Companies
Academic and Research Institutes
Contract Research Organizations
Other End User Verticals
By Region:
North America
Europe
Latin America
East Asia
South Asia & Oceania
The Middle East & Africa (MEA)
Check out More Related Studies Published by Fact.MR:
Paper Diagnostics Market
https://www.factmr.com/report/5454/paper-diagnostics-market
Geriatric Medicines Market
https://www.factmr.com/report/4746/geriatric-medicines-market
Glaucoma Therapeutics Market
https://www.factmr.com/report/4775/glaucoma-therapeutics-market
Monopolar Electrosurgery Market
https://www.factmr.com/report/4845/monopolar-electrosurgery-market
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Hepatocytes Market Size Worth US$ 486 Million with 6.6% CAGR by 2034: Fact.MR Report here
News-ID: 4042278 • Views: …
More Releases from Fact.MR
Bioinformatics Market is Growing at a CAGR of 13.4% by 2034 | Fact.MR Report
The latest report on the Bioinformatics Market, projecting robust growth driven by the increasing demand for genomic research, advancements in artificial intelligence (AI), and the rising adoption of precision medicine. Valued at USD 14.29 billion in 2024, the global market is forecast to expand at a compound annual growth rate (CAGR) of 13.4%, reaching USD 50.25 billion by 2034. This significant growth underscores the critical role of bioinformatics in decoding…
Residential Robotic Vacuum Cleaner Market to Reach USD 11.6 Billion by 2033 | Ke …
Fact.MR today released its latest report on the Residential Robotic Vacuum Cleaner Market, projecting robust growth driven by increasing demand for automation, busy lifestyles, and advancements in smart home technologies. Valued at USD 3.0 billion in 2023, the global market is forecast to expand at a compound annual growth rate (CAGR) of 14.4%, reaching USD 11.6 billion by 2033. This significant growth highlights the rising adoption of robotic vacuum cleaners…
Brain-Computer Interface Market is Estimated to Reach USD 6.5 Billion by 2033
The global brain-computer interface (BCI) market was valued at USD 1.6 billion in 2022 and is projected to reach USD 6.5 billion by 2033, growing at a compound annual growth rate (CAGR) of 13.6% from 2023 to 2033. This expansion reflects the increasing adoption of BCI technologies in medical applications, driven by advancements in neuroscience, AI, and sensor technologies. BCIs enable direct communication between the brain and external devices, offering…
Orally Disintegrating Tablet Market is Projected to Reach USD 72.68 Billion by 2 …
The global orally disintegrating tablet (ODT) market is valued at USD 24.45 billion in 2024 and is forecasted to expand at a compound annual growth rate (CAGR) of 11.5%, reaching USD 72.68 billion by 2034. This robust growth is driven by the increasing demand for patient-friendly dosage forms, particularly among the elderly, pediatric, and dysphagic populations, who benefit from ODTs' ease of administration without water and rapid dissolution. ODTs enhance…
More Releases for Hepatocytes
CD BioGlyco Launches GalNAc-L96 Platform for Targeted siRNA Delivery to Hepatocy …
CD BioGlyco launches a novel GalNAc-L96-based nucleic acid delivery system for precise and stable siRNA/mRNA therapies.
CD BioGlyco has rolled out a newly designed nucleic acid drug delivery [https://www.bioglyco.com/nucleic-acid-drug-delivery-products.html] system for siRNA- and mRNA-based therapeutics.
Built around refined glycosylation chemistry, the platform focuses on improving how molecules like siRNA and mRNA are brought into target cells. Rather than tweaking existing methods, the company has opted for a ground-up redesign that reflects recent…
Primary Hepatocytes Market on Track for 6.6% CAGR Growth Through 2032 - Persiste …
Introduction
The study of liver diseases, drug metabolism, and toxicology has witnessed significant advancements in recent years, with primary hepatocytes playing a crucial role in biomedical research and pharmaceutical development. These cells, derived from liver tissues, are widely used in drug discovery, toxicity testing, and regenerative medicine. As liver-related disorders continue to rise globally, the demand for high-quality primary hepatocytes has surged, driving innovation in cell isolation and culture techniques.
According to…
2023-2029: Mouse Hepatocytes Market Trend And Analysis
Global Info Research announces the release of the report "Global Mouse Hepatocytes Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029" . This report provides a detailed overview of the market scenario, including a thorough analysis of the market size, sales quantity, average price, revenue, gross margin and market share.The report provides an in-depth analysis of the competitive landscape, manufacturer's profiles,regional and national market dynamics, and the opportunities…
Global Primary Hepatocytes Market Trade and Annual Growth Analysis Report Foreca …
The global Primary Hepatocytes Market is estimated to grow at the rate of 6.6% in the upcoming period, by the year 2032. Integration with virtual reality solutions is expected to rule the roost in the forecast period. Augmented reality could be used for accessing information as well as reports while handling patients or without having to leave their existing operations, that too, in a completely hands-free mode, through voice command,…
Primary Hepatocytes Market is growing at an alarming pace with Merck KGaA, Lonza …
Advance Market Analytics published a new research publication on "Primary Hepatocytes Market Insights, to 2027" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Primary Hepatocytes market was mainly driven by the increasing R&D spending across the world.
Get Free Exclusive PDF Sample Copy of…
5G Networks' Performance To Decide The Growth Parameters Of The Primary Hepatocy …
Recent developments in stem cell therapy and the advantages of primary hepatocytes over cell lines have been contributing to the growth of the global primary hepatocytes market. The market was valued at US$ 213.8 Mn in 2021, and is projected to expand at a CAGR of 6.6% over the forecast period (2022-2032).
Rising prevalence of chronic diseases such as cancer, speedy growth in biopharmaceutical industries, and developing focus on R&D are…
